Evidence map›Paper›PMID 39913094›Full record

ArticleInternational braz j urol : official journal of the Brazilian Society of Urology

Percutaneous Cryotherapy and Radiofrequency Ablation of Renal Masses: Multicenter Comparative Analysis with Minimum 3-Year Follow-up.

Umberto Carbonara, Francesco Ditonno, Alp T Beksac, Ithaar Derweesh, Clara Cerrato, Antonio Celia, Giovanni Costa, Lorenzo Bianchi, Jeffrey Elbich, Brandon Wilson and 8 more

Abstract readMulticenter StudyComparative Study
In one paragraph

Article in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Umberto CarbonaraDepartment of Urology, Santa Maria Hospital, Bari, Italy.
Francesco DitonnoDepartment of Urology, Rush University Medical Center, Chicago, IL, USA.
Alp T BeksacGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Ithaar DerweeshDepartment of Urology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Clara CerratoDepartment of Urology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Antonio CeliaDepartment of Urology, San Bassiano Hospital, Bassano Del Grappa, Italy.
Giovanni CostaDepartment of Urology, San Bassiano Hospital, Bassano Del Grappa, Italy.
Lorenzo BianchiDepartment of Urology, University of Bologna, Bologna, Italy.
Jeffrey ElbichDepartment of Radiology, Vascular Interventional Radiology, VCU Health, Richmond, VA, USA.
Brandon WilsonDivision of Urology, VCU Health, Richmond, VA, USA.
Lance J HamptonDivision of Urology, VCU Health, Richmond, VA, USA.
Savio D PandolfoDepartment of Urology, University of L'Aquila, L'Aquila, Italy.
Giuseppe BasileDivision of Experimental Oncology/Unit of Urology; IRCCS San Raffaele Hospital, Milan, Italy.
Fernando J KimDivision of Urology, Denver Health, Denver, CO, USA.
Riccardo SchiavinaDepartment of Urology, University of Bologna, Bologna, Italy.
Umberto CapitanioDivision of Experimental Oncology/Unit of Urology; IRCCS San Raffaele Hospital, Milan, Italy.
Jihad KaoukGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Riccardo AutorinoDepartment of Urology, Rush University Medical Center, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDifferent modalities of percutaneous thermal ablation (PTA) have been used as possible minimally invasive nephron-sparing treatments for small renal masses (SRMs). The present study aimed to compare long-term outcomes of two guidelines-recommended ablative techniques, cryotherapy (CRYO) and radiofrequency ablation (RFA). MATERIALS AND

methodsData of patients with single cT1 solid renal mass undergoing CRYO or RFA between 2004 and 2020 were retrospectively retrieved from a multi-institutional international database. Oncologic outcomes included "technical success", local recurrence-free survival (RFS), distant metastasis-free survival (MFS), and overall survival (OS). Intraoperative and postoperative complications, length of stay (LOS), and re-admission rate within 30 days were registered. Major complications were defined as CD grade ≥III. Baseline features and treatment outcomes were analyzed using descriptive statistics. RFS, MFS, and OS were estimated using the Kaplan-Meier method.

resultsOverall, 643 patients were included, of which 492 (71.2%) underwent CRYO, and 151 (21.8%) RFA, with a median follow-up of 43 and 37 months, respectively (p=0.07). Technical success was achieved in 96.5% of CRYO vs 93.4% of RFA (p=0.09). No difference in terms of overall (CRYO: 10.4% vs RFA: 6%; p=0.1) and "major" (CRYO: 0.8% vs RFA: 1.3; p=0.06) post-operative complications were observed. RFS (CRYO:85.7%; RFA:84.9%, p=0.2), MFS (CRYO: 96.9%; RFA: 95.8%, p=0.4) and OS (CRYO: 89%; RFA: 87.4%; p=0.8) were comparable.

conclusionsCRYO and RFA are both valid minimally invasive options for the treatment of small renal tumors. They are particularly suitable for patients who are not good surgical candidates as they offer very low risk of major procedure-related complications. For the right indication, they both offer favorable mid to long term oncologic outcomes.

Indexed as

CryosurgeryCryotherapyKidney NeoplasmsRadiofrequency AblationAdultAgedDisease-Free SurvivalFemaleFollow-Up StudiesHumansMaleMiddle AgedPostoperative ComplicationsRetrospective StudiesTime FactorsTreatment OutcomeCryotherapyKidney NeoplasmsRadiofrequency Ablation

Identifiers

PMID39913094
PMCPMC11884627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.